New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTeduglutide vs VIP

Teduglutide vs VIP

Side-by-side comparison of key properties, dosing, and research.

Recovery & Repair
Teduglutide
Immune SupportSleep Optimization
VIP
Summary
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
Half-Life
~2 hours; once-daily dosing due to gut-specific residence
~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
Admin Route
SubQ
Intranasal, SubQ, IV
Research
Typical Dose
0.05 mg/kg/day
50 mcg (4 sprays of 12.5 mcg each)
Frequency
Once daily
4x daily
Key Benefits
  • Increases intestinal villus height and absorption surface area
  • Reduces intestinal permeability (leaky gut)
  • FDA-approved for short bowel syndrome
  • Reduces parenteral nutrition dependence in SBS patients
  • Promotes intestinal mucosal healing in IBD
  • Increases tight junction proteins ZO-1 and occludin
  • Potent anti-inflammatory for CIRS and mold illness
  • Improves pulmonary hypertension symptoms
  • Regulates gut motility and IBS symptoms
  • Modulates circadian rhythm and sleep quality
  • Reduces mast cell activation (MCAS)
  • Improves cognitive function in neuroinflammatory conditions
  • Vasodilatory — reduces vascular resistance
Side Effects
  • Injection site reactions
  • Abdominal pain and bloating
  • Nausea
  • Risk of intestinal polyp growth (requires colonoscopy surveillance)
  • +1 more
  • Facial flushing (transient, intranasal)
  • Mild nausea
  • Headache at initiation
  • Hypotension at high doses
  • +1 more
Stacks With